PHARMACOLOGICAL PARAMETERS INFORMATIONS REF
Absorption and bioavailability After oral administration is absorbed predominantly by the small intestine and presents bioavailability of about 50%. 26-29
Distribution Distributed and concentrated mainly in the kidneys, adrenal glands, pancreas and liver. Lower concentrations of MET are found in the lungs and muscles.
Biotransformation MET does not suffer hepatic metabolism.
Excretion Approximately 30-50% of an oral dose of MET is excreted unchanged in the urine over a period of 24 hours and about 30% of the dose is excreted unchanged in the faeces.
Adverse effects Nausea, vomiting, flatulence, diarrhea and abdominal pain, asthenia, headache, skin rash, ovulation induction and lactic acidosis.
Contraindications Drug allergy, creatinine clearance above 1.4 mL/min in women and 1.5 mL/min in men, metabolic acidosis, lactic acidosis, iodinated contrast, hypoxemia, dehydration, sepsis, surgery and liver disease.